DOCSLIB.ORG

2018 GOLD Pocket Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2018 GOLD Pocket Guide GlobalGlobal InitiativeInitiative forfor ChronicChronic ObstructiveObstructive LungLung DiseaseDisease DISTRIBUTE OR COPY NOT DO MATERIAL- COPYRIGHTEDPOCKET GUIDE TO COPD DIAGNOSIS, MANAGEMENT, AND PREVENTION A Guide for Health Care Professionals 2018 REPORT GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE POCKET GUIDE TO COPD DIAGNOSIS, MANAGEMENT, AND PREVENTION A Guide for Health Care Professionals 2018 EDITION DISTRIBUTE OR COPY NOT DO MATERIAL- COPYRIGHTED © 2018 Global Initiative for Chronic Obstructive Lung Disease, Inc. ii GOLD BOARD OF DIRECTORS GOLD SCIENCE COMMITTEE* (2017) (2017) Alvar Agusti, MD, Chair Claus Vogelmeier, MD, Chair Respiratory Institute, University of Marburg Hospital Clinic, IDIBAPS Marburg, Germany Univ. Barcelona and Ciberes Barcelona, Spain Alvar Agusti, MD Nicolas Roche, MD Respiratory Institute, Hospital Hôpital Cochin Bartolome R. Celli, MD Clinic, IDIBAPS Paris, France Brigham and Women’s Hospital Boston, Univ. Barcelona and Ciberes Massachusetts, USA Barcelona, Spain Donald Sin, MD St. Paul’s Hospital, University of Rongchang Chen, MD Antonio Anzueto, MD British Columbia Guangzhou Institute of Respiratory University of Texas Vancouver, Canada Disease Health Science Center Guangzhou, PRC San Antonio, Texas, USA Dave Singh, MD University of Manchester Gerard Criner, MD Peter Barnes, MD Manchester, UK Temple University School of Medicine National Heart and Lung Institute Philadelphia, Pennsylvania, USA London, United Kingdom Robert Stockley, MD University Hospital Peter Frith, MD Jean Bourbeau, MD DISTRIBUTEBirmingham, UK Repatriation General Hospital, Adelaide, McGill University Health Centre South Australia, Australia Montreal, Canada OR Jørgen Vestbo, MD University of Manchester David Halpin, MD Gerard Criner, MD Manchester, England, UK Royal Devon and Exeter Hospital Temple University School of Medicine Devon, UK Philadelphia, Pennsylvania,COPY USA Jadwiga A. Wedzicha, MD Imperial College London M. Victorina López Varela, MD Peter Frith, MD London, UK Universidad de la República Repatriation GeneralNOT Hospital, Montevideo, Uruguay Adelaide, M. Victorina López South Australia,AustraliaDO Varela,MDUniversidad de la Masaharu Nishimura, MD República Hokkaido University School of Medicine David Halpin, MD Hospital Maciel Sapporo, Japan Royal Devon and Exeter Hospital, Montevideo, Uruguay Devon, United Kingdom Claus Vogelmeier, MD University of Marburg MATERIAL-Fernando J. Martinez, MD, MS Marburg, Germany New York-Presbyterian Hospital/ Weill Cornell Medical Center New York, NY USA GOLD PROGRAM DIRECTOR Rebecca Decker,COPYRIGHTED MSJ Fontana, Wisconsin, USA * Disclosure forms for GOLD Committees are posted on the GOLD Website, www.goldcopd.org TABLE OF CONTENTS TABLE OF CONTENTS ......................................... IV SUPPORTIVE, PALLIATIVE, END-OF-LIFE & HOSPICE CARE ................................................. 18 GLOBAL STRATEGY FOR THE DIAGNOSIS, Symptom control and palliative care .......... 18 MANAGEMENT, AND PREVENTION OF COPD ...... 1 OTHER TREATMENTS ....................................... 19 INTRODUCTION ................................................. 1 Oxygen therapy and ventilatory support .... 19 DEFINITION AND OVERVIEW ............................... 1 MANAGEMENT OF STABLE COPD ...................... 21 OVERALL KEY POINTS: .................................. 1 OVERALL KEY POINTS: ................................ 21 WHAT IS CHRONIC OBSTRUCTIVE PULMONARY IDENTIFY AND REDUCE EXPOSURE TO RISK DISEASE (COPD)? ............................................... 2 FACTORS .......................................................... 22 WHAT CAUSES COPD? ....................................... 2 TREATMENT OF STABLE COPD ......................... 23 DIAGNOSIS AND ASSESSMENT OF COPD ............. 4 PHARMACOLOGIC TREATMENT .................. 23 Pharmacologic treatment algorithms ........ 24 OVERALL KEY POINTS: .................................. 4 MONITORING AND FOLLOW-UP ...................... 28 DIAGNOSIS ........................................................ 4 DISTRIBUTE DIFFERENTIAL DIAGNOSIS ................................. 5 MANAGEMENT OF EXACERBATIONS ................. 28 OR ASSESSMENT ..................................................... 6 OVERALL KEY POINTS: ................................ 28 Classification of severity of airflow TREATMENT OPTIONS ..................................... 29 obstruction ................................................... 6 TreatmentCOPY Setting ....................................... 29 Assessment of symptoms ............................. 6 HOSPITAL DISCHARGE AND FOLLOW-UP ......... 33 Combined COPD assessment ........................ 8 NOTCOPD AND COMORBIDITIES .............................. 34 EVIDENCE SUPPORTING PREVENTION AND DO OVERALL KEY POINTS: ................................. 34 MAINTENANCE THERAPY ................................... 9 REFERENCES .................................................... 35 OVERALL KEY POINTS: ..................................9 SMOKING CESSATION ..................................... 10 VACCINATIONS ................................................ 10 Influenza vaccine ................................MATERIAL-........ 10 Pneumococcal vaccine ............................... 10 PHARMACOLOGIC THERAPY FOR STABLE COPD ........................................................................ 11 Bronchodilators .......................................... 11 Beta2-agonists ............................................ 11 Antimuscarinic drugs .................................. 12 COPYRIGHTED Methylxanthines......................................... 12 Combination bronchodilator therapy ......... 12 Anti-inflammatory agents .......................... 14 Inhaled corticosteroids (ICS) ....................... 14 Issues related to inhaled delivery ............... 16 Other pharmacologic treatments ............... 17 REHABILITATION, EDUCATION & SELF- MANAGEMENT ............................................... 18 Pulmonary rehabilitation ........................... 18 iv GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF COPD INTRODUCTION Chronic Obstructive Pulmonary Disease (COPD) represents an important public health challenge and is a major cause of chronic morbidity and mortality throughout the world. COPD is currently the fourth leading cause of death in the world1 but is projected to be the 3rd leading cause of death by 2020. More than 3 million people died of COPD in 2012 accounting for 6% of all deaths globally. Globally, the COPD burden is projected to increase in coming decades because of continued exposure to COPD risk factors and aging of the population.2 This Pocket Guide has been developed from the Global Strategy for the Diagnosis, Management, and Prevention of COPD (2018 Report), which aims to provide a non-biased review of the current evidence for the assessment, diagnosis and treatment of patients withDISTRIBUTE COPD that can aid the clinician. Discussions of COPD and COPD management, evidence levels,OR and specific citations from the scientific literature are included in that source document, which is available from www.goldcopd.org. The tables and figures in this Pocket Guide follow the numbering of the 2018 COPY Global Strategy Report for reference consistency. NOT DEFINITION AND OVERVIEW DO OVERALL KEY POINTS: • Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterizedMATERIAL- by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. • The most common respiratory symptoms include dyspnea, cough and/or sputum production. These symptoms may be under-reported by patients. • The mainCOPYRIGHTED risk factor for COPD is tobacco smoking but other environmental exposures such as biomass fuel exposure and air pollution may contribute. Besides exposures, host factors predispose individuals to develop COPD. These include genetic abnormalities, abnormal lung development and accelerated aging. • COPD may be punctuated by periods of acute worsening of respiratory symptoms, called exacerbations. • In most patients, COPD is associated with significant concomitant chronic diseases, which increase its morbidity and mortality. 1 1 WHAT IS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)? Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. The chronic airflow limitation that is characteristic of COPD is caused by a mixture of small airways disease (e.g., obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative contributions of which vary from person to person (Figure 1.1). Figure 1.1. Etiology, pathobiology and pathology of COPD leading to airflow limitation and clinical manifestations Etiology Smoking and pollutants DISTRIBUTE Host factors OR COPY Pathobiology Impaired lung growth Accelerated declineNOT Lung injury DO Lung & systemic inflammation MATERIAL- Pathology Small airway disorders or abnormalities Emphysema Systemic effects COPYRIGHTEDAirflow limitation Clinical manifestations Persistent airflow Symptoms limitation Exacerbations Comorbidities WHAT CAUSES COPD? Worldwide, the most commonly encountered risk factor for COPD is tobacco smoking. Other types
Load more

Recommended publications
  • Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality
    Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality Please note, this report is designed for double-sided printing American Lung Association Epidemiology and Statistics Unit Research and Health Education Division March 2013 Page intentionally left blank Table of Contents COPD Mortality, 1999-2009 COPD Prevalence, 1999-2011 COPD Hospital Discharges, 1999-2010 Glossary and References List of Tables Table 1: COPD – Number of Deaths by Ethnic Origin and Sex, 1999-2009 Figure 1: COPD – Number of Deaths by Sex, 1999-2009 Figure 2: COPD – Age-Adjusted Death Rates by Ethnic Origin and Sex, 2009 Table 2: COPD – Age-Adjusted Death Rate per 100,000 Population by Ethnic Origin and Sex, 1999- 2009 Figure 3: COPD – Deaths and Age-Adjusted Death Rate by Sex, 2009 Figure 4: COPD – Diagnosed Cases and Evidence of Impaired Lung Function Figure 5: Chronic Bronchitis – Prevalence Rates per 1,000, 2011 Table 3: Chronic Bronchitis – Number of Conditions and Prevalence Rate per 1,000 Population by Ethnic Origin, Sex and Age, 1999-2011 Figure 6: Emphysema – Prevalence Rates per 1,000, 2011 Table 4: Emphysema – Number of Conditions and Prevalence Rate per 1,000 Population by Ethnic Origin, Sex and Age, 1997-2011 Table 5: COPD – Adult Prevalence by Sex and State, 2011 Figure 8: COPD – Age-Adjusted Prevalence in Adults by State, 2011 Table 6: Characteristics Among Those Reporting a Diagnosis of COPD by State (%), 2011 Figure 9: COPD – First-Listed Hospital Discharge Rates per 10,000, 2010 Table 7: COPD – Number of First-Listed Hospital Discharges and Rate per 10,000 Population by Race, Sex and Age, 1999-2010 Figure 9: National Projected Annual Cost of COPD, 2010 Introduction Chronic obstructive pulmonary disease (COPD) is a term which refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing.
    [Show full text]
  • Chronic Obstructive Lung Disease &​Bronchiectasis
    PLEASE CHECK Editing file BEFORE! ​ ​ ​ ​ Chronic Obstructive lung Disease & Bronchiectasis ​ ★ Objectives: ​ 1. Definition of the two conditions 2. Clinical and radiological diagnosis 3. Differential diagnosis 4. General outline of management 5. Create a link to 341 clinical teaching ★ Resources Used in This lecture: Davidson, Guyton and Becker step 1 lecture notes ​ Done by: Mohammad Alkharraz Contact us at: [email protected] Chronic Obstructive Pulmonary Diseases (COPD) COPD contains two diseases which are chronic bronchitis and emphysema ​ ​ ​ ■ COPD is classified under obstructive pulmonary diseases along with other ​(no kidding!)​ diseases such as asthma and bronchiectasis ■ Chronic bronchitis and emphysema are grouped together under COPD because they are both mainly caused by smoking and they usually present together. ​ ■ Brainless pathology textbooks (Robbins) try to confuse us students with “Pink Puffers” and “Blue Bloaters”. Forget about that as it is not clinically relevant1. Let us quickly point out some points (pathology) that are relevant to each disease (chronic bronchitis and emphysema) and then we will discuss the clinical presentation, management, etc. of COPD Chronic bronchitis It is mainly a clinical diagnosis patients cough up lots of sputum for a long period of time ​ ​ “3 months per year for at least 2 consecutive years2” ● Pathogenesis: Cigarette smoke causes hyperplasia of mucus glands which increase the ​ secretion of mucus → mucus plugs cause obstruction of bronchioles→ COPD Emphysema It is mainly a pathological diagnosis. ​ ​ ● Pathogenesis: 1. Pollutants (smoking)→ increased inflammatory mediators in the lung that destroy the lung parenchyma (trypsin and elastase) 2. We have defense mechanisms to fight these inflammatory mediators (alpha1 antitrypsin) ○ However, the amount of inflammatory mediators exceeds our ability to counteract them 3.
    [Show full text]
  • Medicaid Policy Change
    MEDICAID POLICY CHANGE IMMINENT PERIL JUSTIFICATION September 25, 2019 ADVAIR: POLICY CHANGE: LDH is changing the preferred drug list to switch the diskus inhaled powder from preferred to non-preferred and adding the HFA inhaler to the preferred list instead. JUSTIFICATION: This product is used to control symptoms and prevent complications caused by asthma or chronic obstructive pulmonary disease. This change is necessary to make an easier delivery device available for recipients to aid with treatment. Without preferred status, recipients would be required to obtain prior authorization which could delay necessary treatment. This change is needed by 10/1/19 due to the coming seasonal change in weather, including influenza and allergy season, that can significantly exacerbate chronic lung diseases, and so this presents an imminent peril to public health. EFFECTIVE DATE: October 1, 2019 LA Medicaid Preferred Drug List (PDL)/Non-Preferred Drug List (NPDL) Effective Date: July 15October 1, 2019 AG – Authorized Generic DR – Concurrent Prescriptions Must Be Written by Same Prescriber PU – Prior Use of Other Medication is Required AL – Age Limits DS – Maximum Days’ Supply Allowed QL – Quantity Limits BH – Behavioral Health Clinical Authorization Required for Children Younger Than 6 DT – Duration of Therapy Limit RX – Specific Prescription Requirements Years Old BY – Diagnosis Codes Bypass Some Requirements DX – Diagnosis Code Requirements TD – Therapeutic Duplication UN – Drug Use Not Warranted (Needs Appropriate CL – More Detailed Clinical Information
    [Show full text]
  • Respiratory Examination Cardiac Examination Is an Essential Part of the Respiratory Assessment and Vice Versa
    Respiratory examination Cardiac examination is an essential part of the respiratory assessment and vice versa. # Subject steps Pictures Notes Preparation: Pre-exam Checklist: A Very important. WIPE Be the one. 1 Wash your hands. Wash your hands in Introduce yourself to the patient, confirm front of the examiner or bring a sanitizer with 2 patient’s ID, explain the examination & you. take consent. Positioning of the patient and his/her (Position the patient in a 3 1 2 Privacy. 90 degree sitting position) and uncover Exposure. full exposure of the trunk. his/her upper body. 4 (if you could not, tell the examiner from the beginning). 3 4 Examination: General appearance: B (ABC2DEVs) Appearance: young, middle aged, or old, Begin by observing the and looks generally ill or well. patient's general health from the end of the bed. Observe the patient's general appearance (age, Around the bed I can't state of health, nutritional status and any other see any medications, obvious signs e.g. jaundice, cyanosis, O2 mask, or chest dyspnea). 1 tube(look at the lateral sides of chest wall), metered dose inhalers, and the presence of a sputum mug. 2 Body built: normal, thin, or obese The patient looks comfortable and he doesn't appear short of breath and he doesn't obviously use accessory muscles or any heard Connections: such as nasal cannula wheezes. To determine this, check for: (mention the medications), nasogastric Dyspnea: Assess the rate, depth, and regularity of the patient's 3 tube, oxygen mask, canals or nebulizer, breathing by counting the respiratory rate, range (16–25 breaths Holter monitor, I.V.
    [Show full text]
  • The Child with Altered Respiratory Status
    Path: K:/LWW-BOWDEN-09-0101/Application/LWW-BOWDEN-09-0101-016.3d Date: 3rd July 2009 Time: 16:31 User ID: muralir 1BlackLining Disabled CHAPTER 16 The Child With Altered Respiratory Status Do you remember the Diaz fam- Case History leave Lela, the baby sister, ily from Chapter 9, in which with Claudia’s mother, Selma, Jose has trouble taking his asthma medication, and head to the hospital. and in Chapter 4, in which Jose’s little sister, At the hospital the emergency department Lela, expresses her personality even as a new- nurse observes Jose sitting cross-legged and born? Jose is 4 years old and was diagnosed leaning forward on his hands. His mouth is with asthma this past fall, about 6 months ago. open and he is breathing hard with an easily Since that time Claudia, his mother, has audible inspiratory wheeze. He is using his noticed several factors that trigger his asthma subclavicular accessory muscles with each including getting sick, pollen, and cold air. breath. His respiratory rate is 32 breaths per One evening following a warm early-spring minute, his pulse is 112 beats per minutes, day, Jose is outside playing as the sun sets and and he is afebrile. Claudia explains that he the air cools. When he comes inside he was fine; he was outside running and playing, begins to cough. Claudia sets up his nebulizer and then came in and began coughing and and gives him a treatment of albuterol, which wheezing, and she gave him an albuterol lessens his coughing. Within an hour, Jose is treatment.
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis As a Cause of Bronchial Asthma in Children
    Egypt J Pediatr Allergy Immunol 2012;10(2):95-100. Original article Allergic bronchopulmonary aspergillosis as a cause of bronchial asthma in children Background: Allergic bronchopulmonary aspergillosis (ABPA) occurs in Dina Shokry, patients with asthma and cystic fibrosis. When aspergillus fumigatus spores Ashgan A. are inhaled they grow in bronchial mucous as hyphae. It occurs in non Alghobashy, immunocompromised patients and belongs to the hypersensitivity disorders Heba H. Gawish*, induced by Aspergillus. Objective: To diagnose cases of allergic bronchopulmonary aspergillosis among asthmatic children and define the Manal M. El-Gerby* association between the clinical and laboratory findings of aspergillus fumigatus (AF) and bronchial asthma. Methods: Eighty asthmatic children were recruited in this study and divided into 50 atopic and 30 non-atopic Departments of children. The following were done: skin prick test for aspergillus fumigatus Pediatrics and and other allergens, measurement of serum total IgE, specific serum Clinical Pathology*, aspergillus fumigatus antibody titer IgG and IgE (AF specific IgG and IgE) Faculty of Medicine, and absolute eosinophilic count. Results: ABPA occurred only in atopic Zagazig University, asthmatics, it was more prevalent with decreased forced expiratory volume Egypt. at the first second (FEV1). Prolonged duration of asthma and steroid dependency were associated with ABPA. AF specific IgE and IgG were higher in the atopic group, they were higher in Aspergillus fumigatus skin Correspondence: prick test positive children than negative ones .Wheal diameter of skin prick Dina Shokry, test had a significant relation to the level of AF IgE titer. Skin prick test Department of positive cases for aspergillus fumigatus was observed in 32% of atopic Pediatrics, Faculty of asthmatic children.
    [Show full text]
  • Coding Billing
    CodingCoding&Billing FEBRUARY 2020 Quarterly Editor’s Letter Welcome to the February issue of the ATS Coding and Billing Quarterly. There are several important updates about the final Medicare rules for 2020 that will be important for pulmonary, critical care and sleep providers. Additionally, there is discussion of E/M documentation rules that will be coming in 2021 that practices might need some time to prepare for, and as always, we will answer coding, billing and regulatory compliance questions submitted from ATS members. If you are looking for a more interactive way to learn about the 2020 Medicare final rules, there is a webinar on the ATS website that covers key parts of the Medicare final rules. But before we get to all this important information, I have a request for your help. EDITOR ATS Needs Your Help – Recent Invoices for Bronchoscopes and PFT Lab ALAN L. PLUMMER, MD Spirometers ATS RUC Advisor TheA TS is looking for invoices for recently purchased bronchoscopes and ADVISORY BOARD MEMBERS: PFT lab spirometer. These invoices will be used by theA TS to present practice KEVIN KOVITZ, MD expense cost equipment to CMS to help establish appropriate reimbursement Chair, ATS Clinical Practice Committee rates for physician services using this equipment. KATINA NICOLACAKIS, MD Member, ATS Clinical Practice Committee • Invoices should not include education or service contract as those ATS Alternate RUC Advisorr are overhead and cannot be considered by CMS for this portion of the STEPHEN P. HOFFMANN, MD Member, ATS Clinical Practice Committee formula and payment rates. ATS CPT Advisor • Invoices can be up to five years old.
    [Show full text]
  • Breathing Sounds – Determination of Extremely Low Spl
    MATEC Web of Conferences 217, 03001 (2018) https://doi.org/10.1051/matecconf/201821703001 ICVSSD 2018 BREATHING SOUNDS – DETERMINATION OF EXTREMELY LOW SPL M. Harun1*, R. Teoh Y. S1, M. ‘A. A. Ahmad, M. Mohd. Mokji1, You K. Y1, S. A. R. Syed Abu Bakar1, P. I. Khalid1, S. Z. Abd. Hamid1 and R. Arsat1 1 School of Electrical Engineering, Universiti Teknologi Malaysia, *Email: [email protected] Phone: +6075535358 ABSTRACT Breathing sound is an extremely low SPL that results from inspiration and expiration process in the lung. Breathing sound can be used to diagnose persons with complications with breathing. Also, the sound can indicate the effectiveness of treatment of lung disease such as asthma. The purpose of this study was to identify SPL of breathing sounds, over six one octave center frequencies from 63 Hz to 4000 Hz, from the recorded breathing sounds in .wav files. Breathing sounds of twenty participants with normal weight BMI had been recorded in an audiometry room. The breathing sound was acquired in two states: at rest and after a 300 meters walk. Matlab had been used to process the breathing sounds that are in .wav files to come up with SPL (in dB). It has been found out that the SPL of breathing sound of all participants are positive at frequencies 63 Hz and 125 Hz. On the other hand, the SPL are all negatives at frequency 1000 Hz, 2000 Hz and 4000 Hz. In conclusion, SPL of breathing sounds of the participants, at frequencies 250 Hz and 500 Hz that have both positive and negative values are viable to be studied further for physiological and medicinal clues.
    [Show full text]
  • Cryptogenic Organizing Pneumonia—Results of Treatment with Clarithromycin Versus Corticosteroids—Observational Study
    RESEARCH ARTICLE Cryptogenic organizing pneumoniaÐResults of treatment with clarithromycin versus corticosteroidsÐObservational study Elżbieta Radzikowska1*, Elżbieta Wiatr1☯, Renata Langfort2³, Iwona Bestry3³, Agnieszka Skoczylas4, Ewa Szczepulska-Wo jcik2³, Dariusz Gawryluk1☯, Piotr Rudziński5³, Joanna Chorostowska-Wynimko6³, Kazimierz Roszkowski-Śliż1³ 1 III Department of Lung Disease National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland, 2 Pathology Department National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland, 3 Radiology Department National Tuberculosis and Lung Diseases Research Institute, Warsaw, a1111111111 Poland, 4 Geriatrics Department National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, a1111111111 Poland, 5 Thoracic Surgery Department National Tuberculosis and Lung Diseases Research Institute, a1111111111 Warsaw, Poland, 6 Laboratory of Molecular Diagnostics and Immunology National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland a1111111111 a1111111111 ☯ These authors contributed equally to this work. ³ These authors also contributed equally to this work. * [email protected] OPEN ACCESS Abstract Citation: Radzikowska E, Wiatr E, Langfort R, Bestry I, Skoczylas A, Szczepulska-WoÂjcik E, et al. (2017) Cryptogenic organizing pneumoniaÐ Background Results of treatment with clarithromycin versus Cryptogenic organizing pneumonia (COP) is a clinicopathological syndrome of unknown ori- corticosteroidsÐObservational study. PLoS ONE 12(9): e0184739.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Effects of Glycopyrronium on Lung Hyperinflation in COPD Patients Claudio M Sanguinetti1,2
    Sanguinetti Multidisciplinary Respiratory Medicine 2014, 9:19 http://www.mrmjournal.com/content/9/1/19 REVIEW Open Access The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients Claudio M Sanguinetti1,2 Abstract Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation caused by bronchial alterations, small airways disease and parenchymal destruction. In patients with COPD the structural and functional lung alterations can progress more or less rapidly from the initial small airways disease to an overt COPD where a severe expiratory flow limitation takes place. In these conditions, lung hyperinflation develops characterized by increase in functional residual capacity (FRC) and decrease in inspiratory capacity (IC). Thus, IC is an easy and reliable index to monitor lung hyperinflation and to assess the efficacy of bronchodilator drugs. When FRC increases, tidal volume (VT) is located in a more flatted upper part of the P –V curve of the respiratory system and respiratory muscles must sustain a greater elastic workload. Furthermore, due to inadequate time for expiration, there is a positive alveolar pressure at the end of expiration (PEEPi). This represents a further elastic workload for the inspiratory muscles. This impairment of ventilatory mechanics generates dyspnea that in most severely compromised patients occurs also for small efforts causing activity limitation and worst health-related quality of life (HRQoL). Due to these respiratory alterations, bronchodilators are the cornerstone of the long-term treatment of COPD in order to decrease airways resistances, lung hyperinflation and exacerbation rate, and improve patient’s symptoms, exercise tolerance and health status.
    [Show full text]
  • Effects of Replacing Oxitropium with Tiotropium on Pulmonary Function in Patients with COPD: a Randomized Study
    View metadata, citation and similar papers at core.ac.uk ARTICLE IN PRESS brought to you by CORE provided by Elsevier - Publisher Connector Respiratory Medicine (2007) 101, 476–480 Effects of replacing oxitropium with tiotropium on pulmonary function in patients with COPD: A randomized study Cristoforo IncorvaiaÃ, Gian Galeazzo Riario-Sforza, Chiara Pravettoni, Natale Dugnani, Fulvia Paterniti, Laura Pessina, Mario Fumagalli Unit of Pulmonary Rehabilitation, ICP Hospital, via Bignami 1, Viale Molise 69, Milan, Italy Received 3 February 2006; accepted 6 July 2006 KEYWORDS Summary COPD; Background: Inhaled bronchodilators are first line drugs in the treatment of chronic Pulmonary function; obstructive pulmonary disease (COPD). Tiotropium bromide is a recently introduced long- Drug treatment; acting anticholinergic agent able to reduce dyspnoea and COPD exacerbations and to Anticholinergics; improve pulmonary function and quality of life. We designed a study to compare the short- Tiotropium; term efficacy of tiotropium bromide with that of oxitropium bromide in improving Oxitropium pulmonary function in patients with COPD. Methods: Eighty patients were randomized either to continue oxitropium 800 mcg/day or to receive tiotropium 18 mcg/day. Seventy-six (39 in the tiotropium and 37 in the oxitropium group) completed the study. Plethysmography was performed at baseline and after 72 h in all patients. The changes in functional parameters in the two groups were compared by the Mann–Whitney U-test. Results: There were no differences between the two groups regarding age (72.5 vs. 74.2 years), male/female ratio (25/14 vs. 23/14) and pulmonary function at baseline. The changes in spirometric parameters were significantly greater in tiotropium- than in oxitropium-treated patients: mean forced expiratory volume in 1 s (FEV1) increased significantly by 15% vs.
    [Show full text]